Investment
Features
FeesSafety
Academy
More
Pluang+

Compare C3.ai Inc (AI) vs Medpace Holdings Inc (MEDP) Price & Performance

Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

C3.ai Inc vs Medpace Holdings Inc — how do they compare? C3.ai Inc trades at $10.09 (market cap $1.65B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 10.2× C3.ai Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.

AIMEDP
Market Cap
$1.65B$16.90B
Sector
TechnologyTechnology
52-Week High
$19.66$620.59
52-Week Low
$7.76$393.42
Enterprise Value
$1.08B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

C3.ai Inc

C3.ai (AI) trades at $10.125, down 2.64% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported revenue of $389.06 million in 2025 but a net loss of $288.70 million, reflecting persistent unprofitability. Recent news highlights C3.ai being named a leader in AI platforms by Forrester Research (Business Wire, August 10, 2026), though CFO share sales and mixed earnings beats add complexity.

The stock faces significant fundamental challenges with negative margins and cash flow, but analyst consensus is mixed with a $10.20 price target near current levels. Investment opportunity hinges on AI platform adoption growth, while risks include sustained losses, competitive pressure, and high valuation multiples absent earnings.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About C3.ai Inc

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type

Read more on AI

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP